Rich Upton

Rich Upton has over 20 years of experience in venture capital and private equity. In 1999, they founded and became President of Upton Advisors, LLC. In 2006, they joined Home Diagnostics, Inc. as a Board Director. In 2008, they became a General Partner at Harbor Light Captial Partners, a venture capital fund focused on early-stage technology and healthcare companies located in the US. In 2009, they joined Eggrock, Inc. as a Board Director. In 2010, they joined Courtagen Life Sciences, Inc. as a Board Director and Carmell Therapeutics as a Board Director, where they were responsible for developing innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing. In 2011, they joined Alcyone Therapeutics Inc. as a Board Director, where they were responsible for developing breakthrough technologies to treat complex neurological conditions. In 2017, they became a Portfolio Manager at Harbor Light Alternatives Fund and joined Medicinal Genomics Corporation as a Board Director, where they were responsible for developing technologies that help growers, dispensaries, and testing laboratories ensure patients and consumers have access to safe, quality cannabis. In 2018, they joined Anuncia Medical, Inc. as Chairman of the Board, where they were responsible for developing and commercializing innovative technologies for hydrocephalus patients.

Rich Upton received their MBA from the University of Virginia Darden School of Business in 1993, specializing in Finance. Rich received their BA from Amherst College in 1988, with a double major in Economics and English. Rich attended Phillips Exeter Academy from 1982 to 1983.